In vivo amelioration of endogenous antitumor autoantibodies via low-dose P4N through the LTA4H/activin A/BAFF pathway.
about
In vivo amelioration of endogenous antitumor autoantibodies via low-dose P4N through the LTA4H/activin A/BAFF pathway.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh
2016年學術文章
@zh-hant
name
In vivo amelioration of endoge ...... LTA4H/activin A/BAFF pathway.
@en
In vivo amelioration of endoge ...... LTA4H/activin A/BAFF pathway.
@nl
type
label
In vivo amelioration of endoge ...... LTA4H/activin A/BAFF pathway.
@en
In vivo amelioration of endoge ...... LTA4H/activin A/BAFF pathway.
@nl
prefLabel
In vivo amelioration of endoge ...... LTA4H/activin A/BAFF pathway.
@en
In vivo amelioration of endoge ...... LTA4H/activin A/BAFF pathway.
@nl
P2093
P2860
P356
P1476
In vivo amelioration of endoge ...... LTA4H/activin A/BAFF pathway.
@en
P2093
Cheng-Hao Hsieh
Chia-Ching Chang
David E Mold
Hsin-Yi Wu
Jung Chang
Kuang-Wen Liao
Ming-Hua Hsu
Nu-Man Tsai
Ru Chih C Huang
P2860
P304
E7798-E7807
P356
10.1073/PNAS.1604752113
P407
P577
2016-11-17T00:00:00Z